Series B · Healthtech · London, United Kingdom · Founded 2021 · 11–50 employees
Lindus Health is revolutionizing clinical trials as an 'anti-CRO' that runs end-to-end clinical trials up to three times faster than traditional contract research organizations. The company combines AI-powered technology with clinical operations to deliver fixed-price, milestone-based clinical trials that eliminate the typical delays and cost overruns of traditional CROs. They have successfully delivered over 80 clinical trials across the US, UK, and Europe for conditions including diabetes, depression, hypertension, and social anxiety, enrolling over 36,000 patients. In January 2025, they raised a $55 million Series B led by Balderton Capital, bringing their total funding to over $80 million from investors including Peter Thiel and Spotify-backer Creandum.